.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,942,512

« Back to Dashboard

Details for Patent: 5,942,512

Title: Method and composition for treating erectile dysfunction
Abstract:Lipophilic active substance composition and its use in a new method of treating erectile dysfunction by administration thereof, optionally together with a hydrophilic vehicle and optionally an antibacterial agent into the urethra.
Inventor(s): Kock; Nils G. (Goteborg, SE), Lycke; Gerhard (Vastra Frolunda, SE)
Assignee: AMSU Ltd. (Channel Islands, GB)
Filing Date:Jun 07, 1995
Application Number:08/481,609
Claims:1. A method for treating erectile dysfunction in a male individual, comprising:

(a) providing a pharmaceutical composition comprising (i) a first active agent comprising the .alpha..sub.1 -receptor blocking agent phentolamine; (ii) a second active agent selected from the group consisting of additional .alpha..sub.1 -receptor blocking agents, nitroglycerine, vasoactive intestinal polypeptide, and prostaglandins; and (iii) a hydrophilic vehicle in which the first and second active agents are dispersed, wherein the hydrophilic vehicle is suitable for urethral administration and effective to facilitate passage of the first and second active agents through the urethral membrane; and

(b) administering to the urethra of the individual an amount of the composition containing known and therapeutic dosages of the first and second active agents effective to produce penile erection following administration.

2. The method of claim 1, wherein the second active agent is an additional .alpha..sub.1 -receptor blocking agent.

3. The method of claim 2, wherein the second active agent is phenoxybenzamine.

4. The method of claim 2, wherein the second active agent is prazosin.

5. The method of claim 1, wherein the second active agent is nitroglycerine.

6. The method of claim 1, wherein the second active agent is vasoactive intestinal polypeptide.

7. The method of claim 1, wherein the second active agent is a prostaglandin.

8. The method of claim 7, wherein the prostaglandin is selected from the group consisting of prostaglandin E.sub.1, prostaglandin E.sub.2, prostaglandin F.sub.2, and combinations thereof.

9. The method of claim 8, wherein the prostaglandin is prostaglandin E.sub.1.

10. The method of claim 8, wherein the prostaglandin is prostaglandin E.sub.2.

11. The method of claim 8, wherein the prostaglandin is prostaglandin F.sub.2.

12. The method of claim 1, wherein the hydrophilic vehicle is selected from the group consisting of macrogols, fat-free creams, fat-free ointments and combinations thereof.

13. The method of claim 12, wherein the hydrophilic vehicle comprises a macrogol.

14. The method of claim 12, wherein the hydrophilic vehicle comprises a fat-free cream.

15. The method of claim 12, wherein the hydrophilic vehicle comprises a fat-free ointment.

16. The method of claim 7, wherein the hydrophilic vehicle is selected from the group consisting of macrogols, fat-free creams, fat-free ointments and combinations thereof.

17. The method of claim 16, wherein the hydrophilic vehicle comprises a macrogol.

18. The method of claim 16, wherein the hydrophilic vehicle comprises a fat-free cream.

19. The method of claim 16, wherein the hydrophilic vehicle comprises a fat-free ointment.

20. The method of claim 1, wherein the composition further comprises an antibacterial agent.

21. The method of claim 7, wherein the composition further comprises an antibacterial agent.

22. A method for treating erectile dysfunction in a male individual, comprising: (a) providing a pharmaceutical composition comprising (i) a lipophilic active agent for treating erectile dysfunction, wherein the lipophilic active agent comprises phentolamine; and (ii) a hydrophilic vehicle suitable for urethral administration and effective to facilitate passage of the lipophilic active agent through the urethral membrane; and (b) (b) administering to the urethra of the individual an amount of the composition containing a known and therapeutically effective dosage of phentolamine effective to-produce penile erection following administration.

23. The method of claim 22, wherein the hydrophilic vehicle is a macrogol.

24. A pharmaceutical composition for urethral drug administration, comprising a first active agent and a second active agent dispersed in a hydrophilic vehicle, wherein:

(a) the hydrophilic vehicle is suitable for urethral administration and effective to facilitate passage of the first and second active agents through the urethral membrane;

(b) the first active agent comprises the .alpha..sub.1 -receptor blocking agent phentolamine;

(c) the second active agent is selected from the group consisting of additional .alpha..sub.1 -receptor blocking agents, nitroglycerine, vasoactive intestinal polypeptide, and prostaglandins; and

(d) the first and second active agents are present in the composition at concentrations effective to produce penile erection following administration of the composition to the urethra of a male individual.

25. The composition of claim 24, wherein the second active agent is an additional .alpha..sub.1 -receptor blocking agent.

26. The composition of claim 25, wherein the second active agent is phenoxybenzamine.

27. The composition of claim 25, wherein the second active agent is prazosin.

28. The composition of claim 24, wherein the second active agent is nitroglycerine.

29. The composition of claim 24, wherein the second active agent is vasoactive intestinal polypeptide.

30. The composition of claim 24, wherein the second active agent is a prostaglandin.

31. The composition of claim 30, wherein the prostaglandin is selected from the group consisting of prostaglandin E.sub.1, prostaglandin E.sub.2, prostaglandin F.sub.2, and combinations thereof.

32. The composition of claim 31, wherein the prostaglandin is prostaglandin E.sub.1.

33. The composition of claim 31, wherein the prostaglandin is prostaglandin E.sub.2.

34. The composition of claim 31, wherein the prostaglandin is prostaglandin F.sub.2.

35. The composition of claim 24, wherein the hydrophilic vehicle is selected from the group consisting of macrogols, fat-free creams, fat-free ointments and combinations thereof.

36. The composition of claim 35, wherein the hydrophilic vehicle comprises a macrogol.

37. The composition of claim 35, wherein the hydrophilic vehicle comprises a fat-free cream.

38. The composition of claim 35, wherein the hydrophilic vehicle comprises a fat-free ointment.

39. The composition of claim 24, further comprising an antibacterial agent.

40. The composition of claim 30, further comprising an antibacterial agent.

41. A composition for treating erectile dysfunction in a male individual, comprising an active agent for erectile dysfunction dispersed in a hydrophilic vehicle, wherein the active agent comprises phentolamine and the hydrophilic vehicle comprises a macrogol, and further wherein the active agent is present at a concentration effective to produce penile erection following administration of the composition to the urethra of a male individual.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc